Estudo randomizado | Temozolomida adjuvante com ou sem interferon alfa em pacientes com gliomas de alto grau recém-diagnosticados
31 Jan, 2023 | 11:55hComentário: Interferon Alfa Improves Upon Standard Care in High Grade Glioma – Cancer Therapy Advisor
Comentário no Twitter
This phase 3 clinical trial demonstrated interferon alfa + temozolomide prolonged survival time in patients with newly diagnosed high-grade gliomas by median 8 months (18% vs 9% 5yr overall survival), especially with MGMT promoter unmethylated tumors. https://t.co/2yOssnF97G
— JAMA Network Open (@JAMANetworkOpen) January 27, 2023